IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone416-798-3001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.71 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/21/2019 (Estimated)
OptionableOptionable
IntelliPharmaCeutics Intl (OTCMKTS:IPCIF) Frequently Asked Questions
What is IntelliPharmaCeutics Intl's stock symbol?
IntelliPharmaCeutics Intl trades on the OTCMKTS under the ticker symbol "IPCIF."
When did IntelliPharmaCeutics Intl's stock split? How did IntelliPharmaCeutics Intl's stock split work?
Shares of IntelliPharmaCeutics Intl reverse split before market open on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of IntelliPharmaCeutics Intl stock prior to the reverse split would have 10 shares after the split.
How were IntelliPharmaCeutics Intl's earnings last quarter?
IntelliPharmaCeutics Intl Inc (OTCMKTS:IPCIF) released its earnings results on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.70). The business had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.90 million. IntelliPharmaCeutics Intl had a negative net margin of 289.69% and a negative return on equity of 2,640.60%. View IntelliPharmaCeutics Intl's Earnings History.
When is IntelliPharmaCeutics Intl's next earnings date?
What price target have analysts set for IPCIF?
1 brokers have issued 12-month target prices for IntelliPharmaCeutics Intl's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate IntelliPharmaCeutics Intl's share price to reach $6.00 in the next year. This suggests a possible upside of 5,349.6% from the stock's current price. View Analyst Price Targets for IntelliPharmaCeutics Intl.
What is the consensus analysts' recommendation for IntelliPharmaCeutics Intl?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelliPharmaCeutics Intl in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelliPharmaCeutics Intl.
Has IntelliPharmaCeutics Intl been receiving favorable news coverage?
News coverage about IPCIF stock has been trending negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IntelliPharmaCeutics Intl earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for IntelliPharmaCeutics Intl.
Who are some of IntelliPharmaCeutics Intl's key competitors?
Some companies that are related to IntelliPharmaCeutics Intl include Capricor Therapeutics (CAPR), GT Biopharma (GTBP), THERAPIX BIOSCI/S (TRPX), Neurotrope (NTRP), X T L Biopharmaceuticals (XTLB), Trillium Therapeutics (TRIL), BENITEC BIOPHAR/S (BNTC), Uluru (ULUR), Genprex (GNPX), Rexahn Pharmaceuticals (REXN), MusclePharm (MSLP), NeuroVive Pharmaceutical (NEVPF), Reliv International (RELV), Endonovo Therapeutics (ENDV) and Acura Pharmaceuticals (ACUR).
What other stocks do shareholders of IntelliPharmaCeutics Intl own?
Who are IntelliPharmaCeutics Intl's key executives?
IntelliPharmaCeutics Intl's management team includes the folowing people:
- Dr. Isa Odidi, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 61)
- Dr. Amina Odidi, Pres, COO, Co-Chief Scientist Officer & Director (Age 59)
- Mr. Greg Powell, Chief Financial Officer
How do I buy shares of IntelliPharmaCeutics Intl?
Shares of IPCIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IntelliPharmaCeutics Intl's stock price today?
One share of IPCIF stock can currently be purchased for approximately $0.11.
How big of a company is IntelliPharmaCeutics Intl?
What is IntelliPharmaCeutics Intl's official website?
How can I contact IntelliPharmaCeutics Intl?
IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]
MarketBeat Community Rating for IntelliPharmaCeutics Intl (OTCMKTS IPCIF)
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe IPCIF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCIF will underperform the S&P 500 over the long term. You may vote once every thirty days.
